SCHEMBL3784029

SCHEMBL3784029

COC(=O)C1(OC2CCCCO2)CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.42
HPGD P15428 1/20 0.41
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RECQL P46063 1/20 0.39
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
EPHX2 P34913 1/20 0.36
ABL1 P00519 1/20 0.35
RIN1 Q13671 1/20 0.35
CCR2 P41597 1/20 0.35
KDM4E B2RXH2 1/20 0.34
THRB P10828 1/20 0.34
PTPN2 P17706 1/20 0.34
PTPN1 P18031 1/20 0.34
PTPN6 P29350 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29078204 0.79 MAPT (0.34) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL21826746 0.78 MAPT (0.35) ALDH1A1MAPTMEN1KMT2A
SCHEMBL659434 0.74 GPR119 (0.39) EPHX1HPGDUSP2SMN1; SMN2RECQL
SCHEMBL29267044 0.73 ALDH1A1 (0.35) HPGDSMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL17631772 0.73 USP2 (0.45) EPHX1HPGDUSP2SMN1; SMN2RECQL
SCHEMBL12373912 0.73 USP2 (0.45) EPHX1HPGDUSP2SMN1; SMN2RECQL
SCHEMBL9311558 0.72 RECQL (0.50) EPHX1HPGDUSP2SMN1; SMN2RECQL
SCHEMBL8130953 0.72 ATM (0.45) USP2ALDH1A1KDM4E
SCHEMBL3157569 0.72 HPGD (0.41) EPHX1HPGDUSP2SMN1; SMN2ALDH1A1
SCHEMBL662507 0.72 HPGD (0.44) EPHX1HPGDUSP2SMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MITHRIDION, INC. 2018-04-12 US disclosed
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MITHRIDION, INC. 2018-04-12 US disclosed
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating NEUROSOLIS INC (US) 2017-11-02 US disclosed
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating NEUROSOLIS INC (US) 2017-11-02 US disclosed
US-9738633-B2 Cognition enhancing compounds and compositions, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2017-08-22 US disclosed
US-9738633-B2 Cognition enhancing compounds and compositions, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2017-08-22 US disclosed
US-20160340348-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MAPLIGHT THERAPEUTICS, INC. 2016-11-24 US disclosed
US-9403806-B1 Cognition enhancing compounds and compositions, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2016-08-02 US disclosed
US-9403806-B1 Cognition enhancing compounds and compositions, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2016-08-02 US disclosed
US-20160199356-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MAPLIGHT THERAPEUTICS, INC. 2016-07-14 US disclosed
US-20150099765-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating NEUROSOLIS INC (US) 2015-04-09 US disclosed
US-20150099765-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating NEUROSOLIS INC (US) 2015-04-09 US disclosed
US-8853219-B2 Compounds and compositions for cognition-enhancement, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2014-10-07 US disclosed
US-20130274299-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MAPLIGHT THERAPEUTICS, INC. 2013-10-17 US disclosed
US-20130274299-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MAPLIGHT THERAPEUTICS, INC. 2013-10-17 US disclosed
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2012-02-23 US disclosed
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2012-02-23 US disclosed
US-20110263613-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MAPLIGHT THERAPEUTICS, INC. 2011-10-27 US disclosed
WO-2011085406-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2011-07-14 WO disclosed
WO-2010102218-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340348-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 EPHX1 571/4885HPGD 871/4885USP2 3417/4885
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING CHRM3, CHRM4, CHRM5 EPHX1 572/4885HPGD 824/4885USP2 3726/4885
US-20130274299-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 EPHX1 571/4885HPGD 871/4885USP2 3417/4885
US-20150099765-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating CHRM3, ACHE, CHRM4 EPHX1 417/4885HPGD 229/4885USP2 3262/4885
US-20110263613-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING CHRM3, ACHE, CHRM4 EPHX1 417/4885HPGD 229/4885USP2 3262/4885
US-20160199356-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 EPHX1 571/4885HPGD 871/4885USP2 3417/4885
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 EPHX1 571/4885HPGD 871/4885USP2 3417/4885
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating CHRM3, ACHE, CHRM4 EPHX1 417/4885HPGD 229/4885USP2 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.